Symbicort in Severe COPD Management

Primary Evidence and Recommendations

The American Thoracic Society recommends the combination of inhaled corticosteroid/long-acting β-agonist (ICS/LABA) therapy for patients with moderate to very severe COPD to prevent acute exacerbations 1, 2
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests that ICS/LABA combinations, such as Symbicort, are effective options for preventing COPD exacerbations 1, 2, 6

The American College of Chest Physicians recommends prioritizing Symbicort for severe COPD patients with a history of ≥2 moderate exacerbations or ≥1 severe exacerbation in the previous year despite appropriate bronchodilator therapy 3
Patients with blood eosinophil counts >300 cells/μL may benefit from ICS, such as Symbicort, due to a stronger predicted response 4
Symbicort may be considered for patients with features of asthma-COPD overlap syndrome 3

Long-acting anticholinergics (LAMAs) are equally or more effective than ICS/LABA combinations for preventing exacerbations, with lower rates of serious adverse events 5
The risk of pneumonia is increased with ICS use, particularly in older patients and those with lower BMI 3
Patients with blood eosinophils <100 cells/μL may have minimal ICS benefit with increased pneumonia risk 3

For stable severe COPD patients, a first-line LABA/LAMA combination is recommended, with the addition of ICS (triple therapy) if exacerbations continue or if eosinophil count >300 cells/μL 4
Symbicort (ICS/LABA) may be considered as an alternative to LAMA monotherapy since both are effective 1, 2, 6
For acute exacerbations, a short course of systemic corticosteroids (40mg prednisone daily for 5 days) is recommended, with return to maintenance therapy afterward 4